MX9304359A - Derivados de rapamicina. - Google Patents

Derivados de rapamicina.

Info

Publication number
MX9304359A
MX9304359A MX9304359A MX9304359A MX9304359A MX 9304359 A MX9304359 A MX 9304359A MX 9304359 A MX9304359 A MX 9304359A MX 9304359 A MX9304359 A MX 9304359A MX 9304359 A MX9304359 A MX 9304359A
Authority
MX
Mexico
Prior art keywords
derivatives
rapamicina
rapamycin
inhibit
diluents
Prior art date
Application number
MX9304359A
Other languages
English (en)
Inventor
Juan Ignacio Luengo
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX9304359A publication Critical patent/MX9304359A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/416—Evaluating particular organs or parts of the immune or lymphatic systems the spleen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen derivados de rapamicina; composiciones farmacéuticas que comprenden dichos derivados de rapamicina y vehículos o diluyentes farmacéuticamente aceptables; y métodos para usar dichos derivados para inhibir el crecimiento de hongos patógenos, para inhibir la inmunosupresión o para tratar tumores carcinogénicos.
MX9304359A 1992-07-17 1993-07-19 Derivados de rapamicina. MX9304359A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91514692A 1992-07-17 1992-07-17

Publications (1)

Publication Number Publication Date
MX9304359A true MX9304359A (es) 1994-04-29

Family

ID=25435298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304359A MX9304359A (es) 1992-07-17 1993-07-19 Derivados de rapamicina.

Country Status (9)

Country Link
US (1) US5728710A (es)
EP (1) EP0650356B1 (es)
JP (1) JPH07509246A (es)
CN (1) CN1087913A (es)
AU (1) AU4679993A (es)
DE (1) DE69332540T2 (es)
MX (1) MX9304359A (es)
WO (1) WO1994002136A1 (es)
ZA (1) ZA935112B (es)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE37421E1 (en) 1993-07-16 2001-10-23 Smithkline Beecham Corporation Rapamycin derivatives
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
ATE191218T1 (de) * 1993-12-17 2000-04-15 Novartis Ag Rapamycin-derivate als immunosuppressoren
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
WO1996006847A1 (en) * 1994-08-31 1996-03-07 Pfizer Inc. Process for preparing demethylrapamycins
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
PT833828E (pt) * 1995-06-09 2003-02-28 Novartis Ag Derivados de rapamicina
WO1998002441A2 (en) * 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
WO1998009970A2 (en) * 1996-09-09 1998-03-12 American Home Products Corporation Alkylated rapamycin derivatives
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2384160T3 (es) 1999-01-13 2012-07-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) * 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
WO2004007709A2 (en) 2002-07-16 2004-01-22 Biotica Technology Limited Production of polyketides
DK1553940T3 (da) 2002-07-30 2008-06-02 Wyeth Corp Patenterale formuleringer indeholdende en rapamycin-hydroxyester
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
UA80756C2 (en) * 2003-04-22 2007-10-25 Wyeth Corp Antineoplastic combinations of rapomicine and interferon alfa (?) in the treatment of neoplasms
MXPA05012486A (es) 2003-05-20 2006-07-03 Bayer Pharmaceuticals Corp Diaril ureas para enfermedades mediadas por pdgfr.
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US8021849B2 (en) * 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
AU2005319427B2 (en) 2004-12-20 2011-11-03 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
TW200628152A (en) 2004-12-20 2006-08-16 Wyeth Corp Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorsers
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
WO2006095173A2 (en) 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
CA2615254C (en) 2005-07-20 2013-09-24 Novartis Ag Combinations of pyrimidylaminobenzamide bcr-abl inhibitors and mtor inhibitors for the treatment of leukemia
US9006224B2 (en) 2005-11-21 2015-04-14 Novartis Ag Neuroendocrine tumor treatment
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP2245165A4 (en) 2008-01-11 2011-06-01 Massachusetts Eye & Ear Infirm TRANSGENIC CONDITIONAL STOP DIMERICABLE CASPASE ANIMALS
CN105380947A (zh) * 2008-03-11 2016-03-09 万能医药公司 大环内酯化合物及它们的使用方法
EP2254412A4 (en) * 2008-03-11 2012-05-09 Elixir Medical Corp MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THEIR USE
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US10485792B2 (en) 2009-08-26 2019-11-26 Hadasit Medical Research Services & Development Limited Sustained release delivery systems for the prevention and treatment of head and neck cancers
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
JP2013525292A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 有機化合物の組合せ
FI3556774T3 (fi) 2011-03-11 2024-03-15 Beth Israel Deaconess Medical Ct Inc Anti-cd40-vasta-aineita ja niiden käyttötapoja
CA2833962A1 (en) 2011-04-25 2012-11-01 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
RU2014124184A (ru) 2011-11-15 2015-12-27 Новартис Аг Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
NZ631340A (en) 2012-03-23 2016-11-25 Univ Queensland Immunomodulatory agent and uses therefor
WO2013192367A1 (en) 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
US9757432B2 (en) 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
ES2799185T3 (es) * 2013-03-13 2020-12-15 Santen Pharmaceutical Co Ltd Agente terapéutico para la disfunción meibomiana
BR112015023098A2 (pt) 2013-03-14 2017-07-18 Univ Jefferson agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
WO2014184734A1 (en) 2013-05-14 2014-11-20 Novartis Ag Markers associated with mtor inhibition
JP6525971B2 (ja) 2013-06-11 2019-06-05 タカラ バイオ ユーエスエー， インコーポレイテッド タンパク質富化微細小胞、タンパク質富化微細小胞の作製方法及び使用方法
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
WO2015044854A1 (en) 2013-09-24 2015-04-02 Novartis Ag Markers associated with mtor inhibition
CN106061505A (zh) 2014-02-11 2016-10-26 诺华股份有限公司 用于治疗癌症的含pi3k抑制剂的药物组合
AU2015237200A1 (en) 2014-03-27 2016-10-06 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
WO2015171723A1 (en) 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
JP6692798B2 (ja) 2014-09-11 2020-05-13 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア ｍＴＯＲＣ１阻害剤
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
SG10201913491PA (en) 2016-12-22 2020-03-30 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
CN110603038A (zh) 2017-02-10 2019-12-20 塔姆山治疗公司 雷帕霉素类似物
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
JP7381492B2 (ja) 2018-05-01 2023-11-15 レヴォリューション・メディスンズ，インコーポレイテッド Ｍｔｏｒ阻害剤としてのｃ２６－連結ラパマイシン類似体
CR20230103A (es) 2018-05-01 2023-04-11 Revolution Medicines Inc Análogos de rapamicina ligados a c40, c28 y c32 como inhibidores de mtor
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7266043B2 (ja) 2018-05-04 2023-04-27 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
CA3099045A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
MX2020012731A (es) 2018-06-01 2021-02-22 Amgen Inc Inhibidores de kras g12c y metodos para su uso.
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020050890A2 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7382353B2 (ja) 2018-06-15 2023-11-16 ヤンセン ファーマシューティカ エヌ．ベー． ラパマイシン類似体およびその使用
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
AU2019384118A1 (en) 2018-11-19 2021-05-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3897855B1 (en) 2018-12-20 2023-06-07 Amgen Inc. Kif18a inhibitors
PE20211475A1 (es) 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
CA3123044A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
EP3898616A1 (en) 2018-12-20 2021-10-27 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
AU2020210921B2 (en) * 2019-01-22 2022-02-03 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
MX2021010323A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
JP2022522777A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
US11236091B2 (en) 2019-05-21 2022-02-01 Amgen Inc. Solid state forms
CN110343639B (zh) * 2019-07-23 2021-04-27 中国医药集团总公司四川抗菌素工业研究所 一株产15(s)-o-乙基雷帕霉素的链霉菌
CA3147276A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CN114269731A (zh) 2019-08-02 2022-04-01 美国安进公司 Kif18a抑制剂
JP2022542319A (ja) 2019-08-02 2022-09-30 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
WO2021055728A1 (en) 2019-09-18 2021-03-25 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
JP2022552873A (ja) 2019-10-24 2022-12-20 アムジエン・インコーポレーテツド がんの治療におけるｋｒａｓ ｇ１２ｃ及びｋｒａｓ ｇ１２ｄ阻害剤として有用なピリドピリミジン誘導体
IL292438A (en) 2019-10-28 2022-06-01 Merck Sharp & Dohme Small molecules that inhibit the g12c mutant of kras
JP2023515235A (ja) 2019-10-31 2023-04-12 大鵬薬品工業株式会社 ４－アミノブタ－２－エンアミド誘導体及びその塩
CN114901366A (zh) 2019-11-04 2022-08-12 锐新医药公司 Ras抑制剂
CR20220241A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
AU2020377925A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
MX2022005525A (es) 2019-11-08 2022-06-08 Revolution Medicines Inc Compuestos de heteroarilo bicíclicos y usos de estos.
KR20220101125A (ko) 2019-11-14 2022-07-19 암젠 인크 Kras g12c 억제제 화합물의 개선된 합성
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021113665A1 (en) 2019-12-05 2021-06-10 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
KR20220124768A (ko) 2020-01-07 2022-09-14 레볼루션 메디슨즈, 인크. Shp2 억제제 투여 및 암 치료방법
AU2021241718A1 (en) 2020-03-27 2022-10-20 Aeovian Pharmaceuticals, Inc. mTORC1 modulators and uses thereof
EP4139299A1 (en) 2020-04-24 2023-03-01 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
JP7373664B2 (ja) 2020-07-15 2023-11-02 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
MX2023013084A (es) 2021-05-05 2023-11-17 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer.
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin

Also Published As

Publication number Publication date
EP0650356A4 (en) 1995-06-14
DE69332540T2 (de) 2003-07-10
AU4679993A (en) 1994-02-14
US5728710A (en) 1998-03-17
WO1994002136A1 (en) 1994-02-03
JPH07509246A (ja) 1995-10-12
CN1087913A (zh) 1994-06-15
EP0650356A1 (en) 1995-05-03
DE69332540D1 (de) 2003-01-16
EP0650356B1 (en) 2002-12-04
ZA935112B (en) 1994-02-08

Similar Documents

Publication Publication Date Title
MX9304359A (es) Derivados de rapamicina.
MX9304360A (es) Derivados de rapamicina y composiciones farmaceuticas de los mismos.
MX9304361A (es) Derivados de rapamicina.
ES2178037T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.
RU2011138835A (ru) Применение производного рапамицина
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
GEP20002332B (en) Cefalosporin Derivatives
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
FI962487A0 (fi) Rapamysiinijohdannaisia
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
NO302366B1 (no) 4-merkaptoacetylamino-£2|benzazepinon(3)-derivater, og farmasöytisk preparat
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
ES2049690T3 (es) Derivados de taxano, su preparacion y su uso en oncologia.
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
ATE282036T1 (de) Trizyklische antitumor verbindungen mit farnesyl protein transferase inhibierender wirkung
ATE295363T1 (de) Beta-laktame zur herstellung von taxanen mit furyl oder thienyl substituierter seitenkette
ATE251624T1 (de) Granulatimide-derivate zur behandlung von krebs
ES2174921T3 (es) Inhibidores de la proteasa del vih.
NZ334848A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases caused by fungi and bacteria
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
MX9204613A (es) Nitratos organicos, procedimientos para su preparacion y su uso en el tratamiento de enfermedades cardiovasculares
ES2157899T3 (es) Derivados de sampangina utiles como agentes antifungicos y antimicobacterianos.
AR025379A1 (es) 9a-azalidas con actividad antibacteriana.